Chronic oral etoposide in non-small cell lung carcinoma

Vila, Jordi; Palombo, H; Sánchez-Lloret, J.; Agustı́, Carles; Grau, Juan J.; Daniels, M.; Viñolas, Núria; Solá, Carles Miralles; Biete, A.; Ramírez, José

doi:10.1016/0959-8049(92)90126-m

Cited by 19 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 It is available in oral form and is tolerated as palliative monotherapy for patients with metastatic lung cancer at dosages of 1-2 mg/kg/day. 17,18 Here we found etoposide to be effective in suppressing the immune response and enhancing transgene expression at a clinically acceptable dosage.…”

Section: Discussionmentioning

confidence: 75%

Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide

et al. 1998

View full text Add to dashboard Cite

Adenoviral vectors are commonly used in gene therapyimmunized animals treated with etoposide or cyclophostrials because of their efficiency in gene transfer. However, phamide. Neutralizing antibodies to adenovirus and cytotheir use is limited by cellular and humoral immune toxic T lymphocyte (CTL) lysis of virally transduced cells responses that result in temporary transgene expression were significantly suppressed in mice treated with etopoand reduced efficacy of repeated vector administration. We side at 2 or 10 mg/kg/day or cyclophosphamide at 10 hypothesized that certain oncolytic agents commonly used mg/kg/day compared with untreated mice (P Ͻ 0.05). Sigto treat cancer patients could suppress the immune nificantly larger areas of gene transduction were observed response to adenoviral vectors, and enable repeated adenin treated animals compared with untreated mice or the ovirus-mediated cancer gene therapy. Etoposide and mice treated with cyclophosphamide at 2 mg/kg/day (P Ͻ cyclophosphamide were tested for their ability to suppress 0.05). Our results suggest that repeated adenovirally the humoral and cellular immune responses to an adenomediated gene therapy is achievable in cancer patients viral vector in immunocompetent C3H mice. Intratumoral who are concurrently undergoing treatment with chemotransgene expression was monitored in adenovirustherapy.

show abstract

Section: Discussionmentioning

confidence: 75%

Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide

et al. 1998

View full text Add to dashboard Cite

show abstract

“…The fixed daily dose of orally administered etoposide was chosen because it was easy for patients and useful for reducing patients’ hospitalization. The dosage of oral etoposide in our regimen could seem low when compared with dosages in other studies in which oral etoposide was administered at 50 mg/m 2 for 21 days as a single agent [14]; however, we aimed to minimize toxicity and capture the benefit of the synergism between the 2 drugs. In spite of the data of other studies in which gemcitabine and etoposide administration was stopped because of the observed myelotoxicity, our regimen demonstrated a low toxicity and good patient compliance.…”

Section: Discussionmentioning

confidence: 99%

“…Preclinical in vitro studies showed a synergistic cytotoxic effect of the combination of gemcitabine and etoposide in lung cancer cells, and clinical data confirmed a possible synergism of the 2 drugs in combination chemotherapy [11,12,13,14]. Based on these considerations, the combination of gemcitabine plus oral etoposide seems to be a reasonable choice for salvage therapy in advanced ovarian cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

et al. 2011

View full text Add to dashboard Cite

Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in 2 different groups of patients. Group 1 consisted of patients showing disease progression or relapse within 6 months of first-line platinum-based chemotherapy. Group 2 comprised heavily pretreated patients showing progression during the last chemotherapy attempt. Methods: Thirty-four patients were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m² on days 1 and 8 and etoposide was administered orally at 100 mg/day on days 8–12 for 6 courses. Results: Eighteen patients (52.9%) had an objective response and the median duration of the response was 10.3 months. Our chemotherapy regimen showed a low toxicity and good patient compliance. In 5 patients the treatment had to be delayed and in only 2 patients it was discontinued. Conclusions: The combination of gemcitabine and oral etoposide seems to be a safe and effective second-line treatment for platinum-resistant ovarian cancer patients. Additional data on larger series are warranted to better define the activity of this combination regimen.

show abstract

“…Data exploring use of oral etoposide in non-small cell lung cancer (NSCLC) is sparse, primarily consisting of early phase studies done in the 1990s prior to the development of modern platinum-doublet regimens. In phase II trials in treatment-naïve advanced NSCLC, oral etoposide monotherapy at a dose of 50 mg/m 2 for 21 days every 4 weeks offered a RR of 7% to 26% (18)(19)(20). Based on the advantages reported in SCLC, the efficacy of combination therapies with oral etoposide and IV platinum agents was evaluated but these combinations offered modest outcomes and were replaced by more modern chemotherapy doublets (21).…”

Section: Etoposidementioning

confidence: 99%

Oral Chemotherapy for Treatment of Lung Cancer

et al. 2020

View full text Add to dashboard Cite

The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer.

show abstract

Chronic oral etoposide in non-small cell lung carcinoma

Cited by 19 publications

References 13 publications

Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide

Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

Oral Chemotherapy for Treatment of Lung Cancer

Contact Info

Product

Resources

About